GTBP Stock Overview
A clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
GT Biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.06 |
| 52 Week High | US$10.66 |
| 52 Week Low | US$1.92 |
| Beta | 0.57 |
| 11 Month Change | -1.92% |
| 3 Month Change | 41.67% |
| 1 Year Change | -57.87% |
| 33 Year Change | -97.70% |
| 5 Year Change | -95.38% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
We're Keeping An Eye On GT Biopharma's (NASDAQ:GTBP) Cash Burn Rate
Jan 06
GT Biopharma files for $150M mixed shelf offering
Oct 13We Think GT Biopharma (NASDAQ:GTBP) Needs To Drive Business Growth Carefully
Sep 21GT Biopharma GAAP EPS of -$0.10 beats by $0.07
Aug 11Here's Why We're Watching GT Biopharma's (NASDAQ:GTBP) Cash Burn Situation
Jun 08Companies Like GT Biopharma (NASDAQ:GTBP) Are In A Position To Invest In Growth
Nov 24Getting To Know GT Biopharma
Jun 06GT Biopharma names Gregory Berk Chief Medical Officer
Apr 26Shareholder Returns
| GTBP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.8% | 2.5% | 2.2% |
| 1Y | -57.9% | 16.1% | 31.6% |
Return vs Industry: GTBP underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: GTBP underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| GTBP volatility | |
|---|---|
| GTBP Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GTBP's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GTBP's weekly volatility has decreased from 24% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1965 | 2 | Michael Breen | www.gtbiopharma.com |
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors.
GT Biopharma, Inc. Fundamentals Summary
| GTBP fundamental statistics | |
|---|---|
| Market cap | US$6.84m |
| Earnings (TTM) | -US$12.35m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs GTBP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GTBP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$12.35m |
| Earnings | -US$12.35m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.53 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GTBP perform over the long term?
See historical performance and comparison